Dosing of ACE inhibitors in left ventricular dysfunction: Does current clinical dosing provide optimal benefit?

Journal of Cardiovascular Pharmacology

Volumn 34, Issue SUPPL. 1, 1999, Pages

  Pinto, Yigal M ^a   Van Geel, Peter Paul ^a   Alkfaji, H ^a   Van Veldhuisen, Dirk Jan ^a   Van Gilst, Wiek H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

ACE inhibitors; Clinical trials; Genetics; Left ventricular dysfunction; Treatment

Indexed keywords

ALACEPRIL; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRUG METABOLITE; ENALAPRIL; FOSINOPRIL; FOSINOPRILAT; IMIDAPRIL; LISINOPRIL; LISINOPRILAT; PERINDOPRILAT; QUINAPRIL; RAMIPRIL; SPIRAPRIL; TRANDOLAPRIL; UNCLASSIFIED DRUG; ZOFENOPRIL;

CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; HEART LEFT VENTRICLE FAILURE; HUMAN; MEDICAL PRACTICE; PHARMACOGENETICS; PRIORITY JOURNAL;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CLINICAL TRIALS; DRUG ADMINISTRATION SCHEDULE; HUMANS; PATIENT COMPLIANCE; PEPTIDYL-DIPEPTIDASE A; TIME FACTORS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0032887451     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199908001-00003     Document Type: Conference Paper

References (33)

1. van Gilst WH, Kingma JH, Peels KH, Dambrink JH, St John Sutton M. Which patient benefits from early angiotensin-converting enzyme inhibition after myocardial infarction? Results of one-year serial echocardiographic follow-up from the Captopril and Thrombolysis Study (CATS). J Am Coll Cardiol 1996; 28:114-121.
2. Zusman RM. Effects of converting enzyme inhibitors on the renin-angiotensin-aldosterone, bradykinin, and arachidonic acid-prostaglandin systems: correlation of chemical structure and biologic activity. Am J Kidney Dis 1987; 10:13-23.
3. van Wijngaarden J, Pinto YM, van Gilst WH, de Graeff PA, de Langen CD, Wesseling H. Converting enzyme inhibition after experimental myocardial infarction in rats: comparative study between spirapril and zofenopril. Cardiovasc Res 1991; 25:936-942.
4. Esther CR, Marino EM, Howard TE, Machaud A, Corvol P, Capecchi MR, Bernstein KE. The critical role of tissue angiotensin-converting enzyme as revealed by gene targeting in mice. J Clin Invest 1997; 99:2375-2385.
5. Cohen ML, Kurz KD. Angiotensin converting enzyme inhibition in tissues from spontaneously hypertensive rats after treatment with captopril or MK-421. J Pharmacol Exp Ther 1982; 220:63-69.
6. Fabris B, Jackson B, Cubela R, Mendelsohn FAO, Johnston CI. Angiotensin converting enzyme in the rat heart: studies of its inhibition in vitro and ex vivo. Clin Exp Pharmacol Physiol 1989; 16: 309-313.
7. Voors AA, Pinto YM, Buikema H, Urata H, Oosterga M, Rooks G, et al. Dual pathway for angiotensin II formation in human internal mammary arteries. Br J Pharmacol 1998; 125:1028-1032.
8. Urata H, Kinoshita A, Misono KS, Bumpus FM, Husain A. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem 1990; 265: 22348-22357.
9. Zisman LS, Abraham WT, Meixell GE, Vamvakias BN, Quaife RA, Lowes BD, et al. Angiotensin II formation in the intact human heart. Predominance of the angiotensin-converting enzyme pathway. J Clin Invest 1995; 96:1490-1498.
10. Juillerat L, Nussberger J, Menard J, Mooser V, Christen Y, Waeber B, et al. Determinants of angiotensin II generation during converting enzyme inhibition. Hypertension 1990; 16:554-572.
11. Biollaz J, Brunner HR, Gavras I, Waeber B, Gavras H. Anti-hypertensive therapy with MK-421: angiotensin II - renin relationships to evaluate efficacy of converting enzyme blockade. J Cardiovasc Pharmacol 1982; 4:966-972.
12. Lijnen P, Staessen J, Fagard R, Amery A. Increase in plasma aldosterone during prolonged captopril treatment. Am J Cordiol 1982; 49:1561-1563.
13. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990; 86:1343-1346.
14. Danser AHJ, Schalekamp MADH, Bax WA, van den Brink AM, Saxena PR, Riegger GAJ, et al. Angiotensin-converting enzyme in the human heart. Effect of the deletion/insertion polymorphism. Circulation 1995; 92:1387-1388.
15. Ueda S, Meredith PA, Morton JJ, Conell JMC, Elliot HL. ACE (I/D) genotype as a predictor of the magnitude and duration of the response to an ACE inhibitor drug (enalaprilat) in humans. Circulation 1998; 98:2148-2153.
16. Charbonneau F, Elstein E, Overhiser RW, Haber H, Anderson TJ. Differential effects of ACE inhibitors on endothelial dysfunction in coronary disease: response to quinapril predicted by ACE genotype [abstract]. Eur Heart J 1998;(suppl):159
17. van der Kleij FG, Schmidt A, Navis GJ, Haas M, Yilmaz N, de Jong PE, et al, Angiotensin converting enzyme insertion/deletion polymorphism and short-term renal response to ACE inhibition: role of sodium status. Kidney Int 1997; 63 (suppl):S23-S26.
18. Van Veldhuisen DJ, Charlesworth A, Crijns HJGM, Lie KI, Hampton JR. Differences between drug treatment of chronic heart failure between European Countries. Eur Heart J 1999; 20: 666-672.
19. van Veldhuisen DJ, Genth-Zotz S, Brouwer J, Boomsma F, Netzer T, Man in't Veld AJ, et al. High- versus low-dose ACE inhibition in chronic heart failure: a double-blind, placebo-controlled study of imidapril. J Am Coll Cardiol 1998; 32:1811-1818.
20. Esther CR, Marino EM, Howard TE, Machaud A, Corvol P, Capecchi MR, et al. The critical role of tissue angiotensin-converting enzyme as revealed by gene targeting in mice. J Clin Invest 1997; 99:2375-2385.
21. The ATLAS investigators. Comparative effects of a low-dose versus high-dose lisnopril on survival and major events in chronic heart failure: the Assessment of treatment with Lisinopril and Survival (ATLAS) Study [abstract]. Eur Heart J 1998; 19:142.
22. The NETWORK investigators. Clinical outcome with enlapril in symptomatic chornic heart failure:a dose comparison. Eur Heart J 1998; 19:481-489.
23. Schunkert H, Ingelfinger JR, Hirsch AT, Pinto Y, Remme WJ, Jacob H, et al. Feedback regulation of angiotensin converting enzyme activity and mRNA levels by angiotensin II. Circ Res 1993; 72:312-318.
24. Zannad F, Chati Z, Guest M, Plat F. Differential effects of fosinopril and enalapril in patients with mild to moderate chronic heart failure. Fosinopril in Heart Failure Study Investigators. Am Heart J 1998; 136:672-680.
25. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316:1429-1435.
26. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325:293-302.
27. Yusuf S, Pepine CJ, Garces C, Pouleur H, Salem D, Kostis J, et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992; 340:1173-1178.
28. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327:669-677.
29. Swedberg K, Held P, Kjekshus J, Rasmussen K, Ryden L, Wedel H. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II. N Engl J Med 1992; 327:678-684.
30. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of remipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 34:821-828.
31. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995; 345:669-685.
32. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343:1115-1122.
33. Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolaparil in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995; 333:1670-1676.